The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial.
Chiara Cremolini
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Patrizia Trenta
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Gianluca Tomasello
No relevant relationships to disclose
Monica Ronzoni
No relevant relationships to disclose
Libero Ciuffreda
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Chiara Carlomagno
No relevant relationships to disclose
Corrado Boni
No relevant relationships to disclose
Francesca Negri
No relevant relationships to disclose
Carlo Barone
No relevant relationships to disclose
Stefano Vitello
No relevant relationships to disclose
Nicola Giuntini
No relevant relationships to disclose
Andrea Bonetti
No relevant relationships to disclose
Mauro D'Amico
No relevant relationships to disclose
Luca Boni
No relevant relationships to disclose
Alfredo Falcone
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Amgen; Merck Serono; Roche